696 related articles for article (PubMed ID: 31178587)
1. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.
Farnaby W; Koegl M; Roy MJ; Whitworth C; Diers E; Trainor N; Zollman D; Steurer S; Karolyi-Oezguer J; Riedmueller C; Gmaschitz T; Wachter J; Dank C; Galant M; Sharps B; Rumpel K; Traxler E; Gerstberger T; Schnitzer R; Petermann O; Greb P; Weinstabl H; Bader G; Zoephel A; Weiss-Puxbaum A; Ehrenhöfer-Wölfer K; Wöhrle S; Boehmelt G; Rinnenthal J; Arnhof H; Wiechens N; Wu MY; Owen-Hughes T; Ettmayer P; Pearson M; McConnell DB; Ciulli A
Nat Chem Biol; 2019 Jul; 15(7):672-680. PubMed ID: 31178587
[TBL] [Abstract][Full Text] [Related]
2. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
3. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Vaishampayan U; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2024 Apr; 121(15):e2322563121. PubMed ID: 38557192
[TBL] [Abstract][Full Text] [Related]
4. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo.
Kofink C; Trainor N; Mair B; Wöhrle S; Wurm M; Mischerikow N; Roy MJ; Bader G; Greb P; Garavel G; Diers E; McLennan R; Whitworth C; Vetma V; Rumpel K; Scharnweber M; Fuchs JE; Gerstberger T; Cui Y; Gremel G; Chetta P; Hopf S; Budano N; Rinnenthal J; Gmaschitz G; Mayer M; Koegl M; Ciulli A; Weinstabl H; Farnaby W
Nat Commun; 2022 Oct; 13(1):5969. PubMed ID: 36216795
[TBL] [Abstract][Full Text] [Related]
5. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance.
Buscarlet M; Krasteva V; Ho L; Simon C; Hébert J; Wilhelm B; Crabtree GR; Sauvageau G; Thibault P; Lessard JA
Blood; 2014 Mar; 123(11):1720-8. PubMed ID: 24478402
[TBL] [Abstract][Full Text] [Related]
6. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
[TBL] [Abstract][Full Text] [Related]
7. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors - a review of patent literature from 2019-June 2023.
Lee ECY; Reichl KD; Gopalsamy A
Expert Opin Ther Pat; 2024 May; ():1-19. PubMed ID: 38742308
[TBL] [Abstract][Full Text] [Related]
9. Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers.
Schick S; Rendeiro AF; Runggatscher K; Ringler A; Boidol B; Hinkel M; Májek P; Vulliard L; Penz T; Parapatics K; Schmidl C; Menche J; Boehmelt G; Petronczki M; Müller AC; Bock C; Kubicek S
Nat Genet; 2019 Sep; 51(9):1399-1410. PubMed ID: 31427792
[TBL] [Abstract][Full Text] [Related]
10. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38464081
[TBL] [Abstract][Full Text] [Related]
11. The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer.
Hodges C; Kirkland JG; Crabtree GR
Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27413115
[TBL] [Abstract][Full Text] [Related]
12. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong
Yang L; Tu W; Huang L; Miao B; Kaneshige A; Jiang W; Leng L; Wang M; Wen B; Sun D; Wang S
J Med Chem; 2023 Aug; 66(15):10761-10781. PubMed ID: 37523716
[TBL] [Abstract][Full Text] [Related]
13. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Cantley J; Ye X; Rousseau E; Januario T; Hamman BD; Rose CM; Cheung TK; Hinkle T; Soto L; Quinn C; Harbin A; Bortolon E; Chen X; Haskell R; Lin E; Yu SF; Del Rosario G; Chan E; Dunlap D; Koeppen H; Martin S; Merchant M; Grimmer M; Broccatelli F; Wang J; Pizzano J; Dragovich PS; Berlin M; Yauch RL
Nat Commun; 2022 Nov; 13(1):6814. PubMed ID: 36357397
[TBL] [Abstract][Full Text] [Related]
14. Crystallization of VHL-based PROTAC-induced ternary complexes.
Wijaya AJ; Farnaby W; Ciulli A
Methods Enzymol; 2023; 681():241-263. PubMed ID: 36764760
[TBL] [Abstract][Full Text] [Related]
15. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
16. Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design.
Farnaby W; Koegl M; Roy MJ; Whitworth C; Diers E; Trainor N; Zollman D; Steurer S; Karolyi-Oezguer J; Riedmueller C; Gmaschitz T; Wachter J; Dank C; Galant M; Sharps B; Rumpel K; Traxler E; Gerstberger T; Schnitzer R; Petermann O; Greb P; Weinstabl H; Bader G; Zoephel A; Weiss-Puxbaum A; Ehrenhöfer-Wölfer K; Wöhrle S; Boehmelt G; Rinnenthal J; Arnhof H; Wiechens N; Wu MY; Owen-Hughes T; Ettmayer P; Pearson M; McConnell DB; Ciulli A
Nat Chem Biol; 2019 Aug; 15(8):846. PubMed ID: 31267096
[TBL] [Abstract][Full Text] [Related]
17. The ATPase module of mammalian SWI/SNF family complexes mediates subcomplex identity and catalytic activity-independent genomic targeting.
Pan J; McKenzie ZM; D'Avino AR; Mashtalir N; Lareau CA; St Pierre R; Wang L; Shilatifard A; Kadoch C
Nat Genet; 2019 Apr; 51(4):618-626. PubMed ID: 30858614
[TBL] [Abstract][Full Text] [Related]
18. Roles of chromatin remodeling BAF complex in neural differentiation and reprogramming.
Narayanan R; Tuoc TC
Cell Tissue Res; 2014 Jun; 356(3):575-84. PubMed ID: 24496512
[TBL] [Abstract][Full Text] [Related]
19. Loss of function of SWI/SNF chromatin remodeling genes leads to genome instability of human lung cancer.
Huang HT; Chen SM; Pan LB; Yao J; Ma HT
Oncol Rep; 2015 Jan; 33(1):283-91. PubMed ID: 25370573
[TBL] [Abstract][Full Text] [Related]
20. GNE-235: A Lead Compound Selective for the Second Bromodomain of PBRM1.
Cochran AG; Flynn M
J Med Chem; 2023 Sep; 66(18):13116-13134. PubMed ID: 37702400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
